GABAergic function in Alzheimer's disease: Evidence for dysfunction and potential as a therapeutic target for the treatment of behavioral and psychological symptoms of dementia

Canadian Journal of Psychiatry

Volumn 49, Issue 7, 2004, Pages 439-453

  Lanctôt, Krista L ^a,b   Herrmaan, Nathan ^a,b   Mazzotta, Paolo ^a   Khan, Lyla R ^a   Ingber, Neil ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Behavioural and psychological symptoms of dementia; GABA; Neurochemical pathology

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; DIPHENHYDRAMINE; FLUMAZENIL; FLUNITRAZEPAM; GABAPENTIN; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; IOMAZENIL; LAMOTRIGINE; LORAZEPAM; OXAZEPAM; THIORIDAZINE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZOLPIDEM;

ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ATAXIA; BEHAVIOR THERAPY; DEMENTIA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GERONTOPSYCHIATRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMITTER RELEASE; PATIENT CARE; POPULATION RESEARCH; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; REVIEW; SEDATION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY;

EID: 4043070505     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900705     Document Type: Review

References (146)

1. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, and others. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
2. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.
3. Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, and others. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257-63.
4. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64-S78.
5. Hardy J, Adolfsson R, Alafuzoff I, Bucht G, Marcusson J, Nyberg P, and others. Transmitter deficits in Alzheimer's disease. Neurochem Int 1985;7:545-63.
6. Reinikainen KJ, Paljarvi L, Huuskonen M, Soininen H, Laakso M, Riekkinen PJ. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J Neurol Sci 1988;84:101-16.
7. Lanctôt KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001;13:5-21.
8. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-6.
9. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-83.
10. Iversen LL, Bloom FE. Studies of the uptake of 3H-GABA and (3H)glycine in slices and homogenates of rat brain and spinal cord by electron microscopic autoradiography. Brain Res 1972;41:131-43.
11. Sivilotti L, Nistri A. GABA receptor mechanisms in the central nervous system. Prog Neurobiol 1991;36:35-92.
12. Curtis DR, Felix D, McLellan H. GABA and hippocampal inhibition. Br J Pharmacol 1970;40:881-3.
13. Storey E, Beal MF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993;116:1201-22.
14. Nobrega JN, Richter A, McIntyre Burnham W, Lôscher W. Alterations in the brain GABAA/benzodiazepine receptor chloride ionophore complex in a genetic model of paroxysmal dystonia: a quantitative autoradiographic analysis. Neuroscience 1995;64:229-39.
15. Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 1995;38:578-91.
16. van Kammen DP, Petty F, Kelley ME, Kramer GL, Barry EJ, Yao JK, and others. GABA and brain abnormalities in schizophrenia. Psychiatry Res 1998;82:25-35.
17. Keverne EB. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res Bull 1999;48:467-73.
18. Eichelman B. Neurochemical basis of aggressive behavior. Psychiatri Ann 1987;17:371-4.
19. Adams DB, Boudreau W, Cowan CW, Kokonowski C, Oberteuffer K, Yohay K. Offense produced by chemical stimulation of the anterior hypothalamus of the rat. Physiol Behav 1993;53:1127-32.
20. Roeling TA, Kruk MR, Schuurmans R, Veening JG. Behavioural responses of bicucculline methiodide injections into the ventral hypothalamus of freely moving, socially interacting rats. Brain Res 1993;615:121-7.
21. Panksepp J. Drugs and stimulus-bound attack. Physiol Behav 1971;6:317-20.
22. Funderburk WH, Foxwell MH, Hakala MW. Effects of psychotherapeutic drugs on hypothalamic-induced hissing in cats. Neuropharmacology 1970;9:1-7.
23. Malick JB, Goldberg ME. Effects of a choline acetyltransferase inhibitor on self-stimulatory behavior in the rat. Arch Int Pharmacodyn Ther 1970;184:252-6.
24. Delgado JMR. Antiaggressive effects of chlordiazepoxide. New York: Raven Press; 1973.
25. Decker MW, McGaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991;7:151-68.
26. Zorumski CF, Isenberg KE. Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry 1991;148:162-73.
27. Gu Z, Zhong P, Yan Z. Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices. J Biol Chem 2003;278:17546-56.
28. Sherif FM. GABA-transaminase in brain and blood platelets: basic and clinical aspects. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1219-33.
29. Chebib M, Johnston GA. The 'ABC' of GABA receptors: a brief review. Clin Exp Pharmacol Physiol 1999;26:937-40.
30. Bormann J. The 'ABC' of GABA receptors. Trends Pharmacol Sci 2000;21:16-9.
31. Howell O, Atack J, Dewar D, McKeman M, Sur C. Density and Pharmacology of alpha-5 subunit-containing GABA A receptors are preserved in hippocampus of Alzheimer's disease. Neuroscience 2000;98:669-75.
32. Simpson PB, Woollacott AJ, Pillai GV, Maubach KA, Hadingham KL, Martin K, and others. Pharmacology of recombinant human GABA(A) receptor subtypes measured using a novel pH-based high-throughput functional efficacy assay. J Neurosci Methods 2000;99:91-100.
33. McKeman RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, and others. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype [comments]. Nat Neurosci 2000;3:587-92.
34. Doble A. New insights into the mechanism of action of hypnotics. J Psychopharmacol 1999;13:S11-S20.
35. Butterfield A, Pocernich CB. The glutamatergic system and Alzheimer's disease. CNS Drugs 2003;17:641-52.
36. Abe S, Suzuki T, Ito T, Baba A, Hori T, Kurita H, and others. Differential expression of GABA(A) receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration. Synapse 2000;38:51-60.
37. Lloyd K, Morselli P. Psychopharmacology of GABAergic drugs. In: Meltzer H, Meltzer HS, editors. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p 183-95.
38. Cooper JR, Bloom FE, Roth RH. Amino acid transmitters. In: The biochemical basis of neuropharmacology. New York: Oxford University Press; 1996. p 126-93.
39. Yew DT, Li WP, Webb SE, Lai HW, Zhang L. Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison. Exp Gerontol 1999;34:117-33.
40. Mohanakrishnan P, Fowler AH, Vonsattel JP, Husain MM, Jolles PR, Liem P, and others. An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res 1995;102:503-10.
41. Perry TL, Yong VW, Bergeron C, Hansen S, Jones K. Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease. Ann Neurol 1987;21:331-6.
42. Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 1988;111:785-99.
43. Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, Iizuka R. Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 1986;19:263-9.
44. Arai H, Kobayashi K, Ichimiya Y, Kosaka K, Iizuka R. A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients. Neurobiol Aging 1984;5:319-21.
45. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. BMJ (Clin Res Ed) 1984;288:961-4.
46. Perry EK, Atack JR, Perry RH, Hardy JA, Dodd PR, Edwardson JA, and others. Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal. J Neurochem 1984;42:1402-10.
47. Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB. A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Ann Neurol 1986;20:616-21.
48. Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982;105:313-30.
49. Tarbit I, Perry EK, Perry RH, Blessed G, Tomlinson BE. Hippocampal free amino acids in Alzheimer's disease. J Neurochem 1980;35:1246-9.
50. Procter AW, Francis PT, Stratmann GC, Bowen DM. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochem Res 1992;17:917-22.
51. Greenamyre JT, Penney JB, D'Amato CJ, Young AB. Dementia of the Alzheimer's type: changes in hippocampal L-[3H]glutamate binding. J Neurochem 1987;48:543-51.
52. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 1988;23:404-6.
53. Jansen KL, Faull RL, Dragunow M, Synek BL. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors an autoradiographic study. Neuroscience 1990;39:613-27.
54. Carlson MD, Penney JB, Jr, Young AB. NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiol Aging 1993;14:343-52.
55. Cross AJ, Crow TJ, Ferrier IN, Johnson JA. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol Aging 1986;7:3-7.
56. Owen F, Poulter M, Waddington JL, Mashal RD, Crow TJ. [3H]R05-4864 and [3H]flunitrazepam binding in kainate-lesioned rat striatum and in temporal cortex of brains from patients with senile dementia of the Alzheimer type. Brain Res 1983;278:373-5.
57. Sedvall G, Nyback H, Farde L, Persson A. Neurotransmitter receptor imaging in Alzheimer's disease. J Neural Transm Suppl 1987;24:43-8.
58. Griffiths PD, Perry RH, Crossman AR. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett 1994;169:68-72.
59. Seidl R, Cairns N, Singewald N, Kaehler ST, Lubec G. Differences between GABA levels in Alzheiemer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn-Schmiedeberg's Arch Pharmacol 2001;363:139-45.
60. Nägga K, Bogdanovic N, Marcusson J. GABA transporters (GAT-1) in Alzheimer's disease. J Neural Transm 1999;106:1141-9.
61. Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ. Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res 1978;159:477-81.
62. Hardy J, Cowburn R, Barton A, Reynolds G, Dodd P, Wester P and others. A disorder of cortical GABAergic innervation in Alzheimer's disease. Neurosci Lett 1987;73:192-6.
63. Chu DC, Penney JB, Jr., Young AB. Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer's disease. Neurosci Lett 1987;82:246-52.
64. Chu DC, Penney JB Jr, Young AB. Cortical GABAB and GABAA receptors in Alzheimer's disease: a quantitative autoradiographic study. Neurology 1987;37:1454-9.
65. Vogt BA, Crino PB, Volicer L. Laminar alterations in gamma-aminobutyric acidA, muscarinic, and beta adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's disease. J Neurochem 1991;57:282-90.
66. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-9.
67. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979;171:319-27.
68. Nakamura S. Senile dementia and presenile dementia. Tohoku J Exp Med 1990;161 (Suppl):49-60.
69. Yates CM, Butterworth J, Tennant MC, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem 1990;55:1624-30.
70. Boissiere F, Faucheux B, Duyckaerts C, Hauw JJ, Agid Y, Hirsch EC. Striatal expression of glutamic acid decarboxylase gene in Alzheimer's disease. J Neurochem 1998;71:767-74.
71. Aoyagi T, Wada T, Nagai M, Kojima F, Harada S, Takeuchi T, and others. Increased gamma-aminobutyrate aminotransferase activity in brain of patients with Alzheimer's disease. Chem Pharm Bull (Tokyo) 1990;38:1748-9.
72. Sherif F, Gottfries CG, Alafuzoff I, Oreland L. Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1992;4:227-40.
73. Sherif F, Ahmed SS, Eriksson L. Brain aminobutyrate aminotransferase activity in Alzheimer's disease [letter]. Neurodegeneration 1995;4:114-5.
74. Smith CC, Bowen DM, Sims NR, Neary D, Davison AN. Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. Brain Res 1983;264:138-41.
75. Foster NL, VanDerSpek AF, Aldrich MS, Berent S, Hichwa RH, Sackellares JC, and others. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography. J Cereb Blood Flow Metab 1987;7:415-20.
76. Fukuchi K, Hashikawa K, Seike Y, Moriwaki H, Oku N, Ishida M, and others. Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease. J Nucl Med 1997;38:467-70.
77. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol 1995;52:314-7.
78. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, and others. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999;13:309-15.
79. Wyper D, Kelly C, Patterson J. Single photon emission computed tomography in Alzheimer's disease: a review of cerebral perfusion and acetylcholine muscarinic receptor imaging and a novel study of the GABA/benzodiazepine system. Inter J Geriatr Psychopharmacol 1998;1:126-33.
80. Jimenez-Jimenez FJ, Molina JA, Gomez P, Vargas C, de Bustos F, Benito-Leon J, and others. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm 1998;105:269-77.
81. Oishi M, Mochizuki Y, Yoshihashi H, Takasu T, Nakano E. Laboratory examinations correlated with severity of dementia. Ann Clin Lab Sci 1996;26:340-5.
82. Weiner MF, Speciale SG, Risser RC, Kramer GL, Petty F. Cerebrospinal fluid and plasma gamma-aminobutyric acid in Alzheimer's disease. Biol Psychiatry 1996;40:933-4.
83. Tohgi H, Abe T, Takahashi S, Kimura M. A selective reduction of excitatory amino acids in cerebrospinal fluid of patients with Alzheimer type dementia compared with vascular dementia of the Binswanger type. Neurosci Lett 1992;141:5-8.
84. Tosca P, Canevari L, Di Paolo E, Ferrari R, Verze S, Zerbi F, and others. Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy. Acta Neurol Scand 1992;85:430-5.
85. Pomara N, Deptula D, Galloway MP, LeWitt PA, Stanley M. CSF GABA in caregiver spouses of Alzheimer patients. Am J Psychiatry 1989;146:787-8.
86. Kuroda H. Gamma-aminobutyric acid (GABA) in cerebrospinal fluid. Acta Med Okayama 1983;37:167-77.
87. Bareggi SR, Franceschi M, Bonini L, Zecca L, Smime S. Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age or disease-related modifications? Arch Neurol 1982;39:709-12.
88. Mohr E, Bruno G, Foster N, Gillespie M, Cox C, Hare TA, and others. GABA-agonist therapy for Alzheimer's disease. Clin Neuropharmacol 1986;9:257-63.
89. Zimmer R, Teelken AW, Trieling WB, Weber W, Weihmayr T, Lauter H. Gamma-aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer's type. Arch Neurol 1984;41:602-4.
90. Manyam NV, Katz L, Hare TA, Gerber JC, Grossman MH. Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Arch Neurol 1980;37:352-5.
91. Enna SJ, Stem LZ, Wastek GJ, Yamamura HI. Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. Arch Neurol 1977;34:683-5.
92. Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer's Disease patients living in the community. J Clin Psychiatry 2003;64:466-72.
93. Ancill RJ, Carlyle WW, Liang RA, Holliday SG. Agitation in the demented elderly: a role for benzodiazepines? Int Clin Psychopharmacol 1991;6:141-6.
94. Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc 1998;46:620-5.
95. Smeraski PJ. Clonazepam treatment of multi-infarct dementia. J Geriatr Psychiatry Neurol 1988;1:47-8.
96. Freinhar JP, Alvarez WA. Clonazepam treatment of organic brain syndromes in three elderly patients. J Clin Psychiatry 1986;47:525-6.
97. Ginsburg ML. Clonazepam for agitated patients with Alzheimer's disease [letter]. Can J Psychiatry 1991;36:237-8.
98. Calkin PA, Kunik ME, Orengo CA, Molinari V, Workman R. Tolerability of clonazepam in demented and non-demented geropsychiatric patients. Int J Geriatr Psychiatry 1997;12:745-9.
99. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: A double-blind comparison of a phenothiazine and a benzodiazepine. South Med J 1975;68:719-24.
100. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study. J Am Geriatr Soc 1973;21:546-51.
101. Conn DK, Ferguson I, Mandelman K, Ward C. Psychotropic drug utilization in long-term care facilities for the elderly in Ontario, Canada. Int Psychogeriatr 1999;11:223-33.
102. Fritz J, Stewart JT. Lorazepam treatment of resistive aggression in dementia [letter]. Am J Psychiatry 1990;147:1250.
103. Sunderland T, Weingartner H, Cohen RM, Tariot PN, Newhouse PA, Thompson KE, and others. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology (Berl) 1989;99:129-33.
104. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley Jr CM, and others. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacol 2002;26:494-504.
105. Sanders JF. Evaluation of oxazepam and placebo in emotionally disturbed aged patients. Geriatrics 1965;20:739-46.
106. Beber CR. Management of behavior in the institutionalized aged. Dis Nerv Syst 1965;26:591-5.
107. Chesrow EJ, Kaplitz, SE, Veltra, H, Breme JT, Marquardt GH. Blind study of oxazepam in the management of geriatric patients with behaivoral problems. Clin Med 1965;71:1001-5.
108. Coccaro EF, Kramer E, Zemishlany Z, Thorne A, Rice CM, Giordani B, and others. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990;147:1640-5.
109. Herz LR, Volicer L, Ross V, Rheaume Y. A single-case-study method for treating resistiveness in patients with Alzheimer's disease. Hosp Community Psychiatry 1992;43:720-4.
110. Shelton PS, Hocking LB. Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother 1997;31:319-22.
111. Fastborn J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:14-7.
112. Marin DB, Greenwald BS. Carbamazepine for aggressive agitation in demented patients during nursing care [letter]. Am J Psychiatry 1989;146:805.
113. Patterson JF. Carbamazepine for assaultive patients with organic brain disease. Psychosomatics 1987;28:579-81.
114. Patterson JF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol 1988;1:21-3.
115. Leibovici A, Tariot PN. Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatry Neurol 1988;1:110-2.
116. Essa M. Carbamazepine in dementia. J Clin Psychopharmacol 1986;6:234-6.
117. Anton RF, Waid LR, Fossey M, AuBuchon P. Case report of carbamazepine treatment of organic brain syndrome with psychotic features. J Clin Psychopharmacol 1986;6:232-4.
118. Lemke MR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry 1995;56:354-7.
119. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics [comments]. J Clin Psychiatry 1990;51:115-8.
120. Tariot PN, Jakimovich LJ, Erb R, Cox C, Lanning B, Irvine C, and others. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. J Clin Psychiatry 1999;60:684-9.
121. Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Asnis J, and others. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994;42:1160-6.
122. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, and others. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54-61.
123. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment resistant outpatients with Alzheimer's disease. Am J Geriatr Psychiatry 2001;9:400-5.
124. Gupta S, O'Connell R, Parekh A, Krotz B, Stockwell D. Efficacy of valproate for agitation and aggression in dementia: case reports. Int J Geriatr Psychopharmacol 1998;1:244-8.
125. Sival RC, Haffmans PM, van Gent PP, van Nieuwkerk JF. The effects of sodium valproate on disturbed behavior in dementia [letter]. J Am Geriatr Soc 1994;42:906-7.
126. Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997;58:351-4.
127. Fahs H, Potiron G, Senon JL, Perivier E. Anticonvulsants in agitation and behavior disorders in demented subjects: report of 8 cases. Encephale 1999;25:169-74.
128. Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998;43:69-72.
129. Haas S, Vincent K, Holt J, Lippmann S. Divalproex: a possible treatment alternative for demented, elderly aggressive patients. Ann Clin Psychiatry 1997;9:145-7.
130. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997;5:344-51.
131. Home M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes [letter]. J Clin Psychiatry 1995;56:430-1.
132. Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995;7:314-9.
133. Sandbom WD, Bendfeldt F, Hamdy R. Valproic acid for physically aggressive behaviour in geriatric patients. Am J Geriatr Psychiatry 1995;3:239-42.
134. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993;6:205-9.
135. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, and others. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58-66.
136. Tariot PN, Schneider LS, Mintzer JE, Cutler AJ, Cunningham M, Thomas J, and others. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 2001;62:51-67.
137. Sival RC, Haffmans J, Jansen PAF, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia-a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002;17:579-85.
138. Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry 2001;158:128-30.
139. So CC, Wong KF. Valproate-associated dysmyelopoiesis in elderly patients. Am J Clin Pathol 2002;118:225-8.
140. Herrmann N, Lanctôt K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000;20:90-3.
141. Hawkins JW, Tinklenberg JR, Sheikh JI, Peyser CE, Yesavage JA. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry 2000;8:221-5.
142. Roane DM, Feinberg TE, Meckler L, Miner CR, Scicutella A, Rosenthal RN. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci 2000;12:40-3.
143. Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, and others. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290:131-4.
144. Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, and others. Benzodiazepine actions mediated by specific gamma-aminobutyric acid (A) receptor subtypes. Nature 1999;401:796-800.
145. Kardos J. Recent advances in GABA research. Neurochem Int 1999;34:353-8.
146. Vekovischeva OY, Haapalinna A, Sarviharju M, Honkanen A, Korpi ER. Cerebellar GABA(A) receptors and anxiolytic action of diazepam. Brain Res 1999;837:184-7.